The world’s energy demand is rising, and NREL’s ULIS power module could help meet it. Demand for energy worldwide is climbing rapidly, driven in part by power hungry data centers that support ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. White House responds to Pope Leo’s rebuke of Trump peace plan for Ukraine After winning his ...

If only they were robotic! Instead, chatbots have developed a distinctive — and grating — voice. Credit...Illustration by Giacomo Gambineri Supported by By Sam Kriss In the quiet hum of our digital ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

A growing number of special education teachers say they use artificial intelligence platforms to draft all or part of students’ individualized education programs, even as many districts lack policies ...

Rachel is a freelancer based in Echo Park, Los Angeles and has been writing and producing content for nearly two decades on subjects ranging from tech to fashion, health and lifestyle to entertainment ...

GARDEN CITY, Long Island (WABC) -- A college student on Long Island says he was wrongly accused of using artificial intelligence to write an essay, and now he's suing his university. Adelphi ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...